Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : How To Write Covered Calls - An Ongoing Real Case Study! -- Ignore unavailable to you. Want to Upgrade?

To: Steve J. who wrote (5623)	10/24/1997 10:05:00 PM
From: Herm	Read Replies (1) \| Respond to of 14162

Howdy Steve J, I would have to say VVUS is going to test this recent high of $41. The fact that most bio-technology are trading at P/Es of 27.7 and VVUS is at a 7% discount makes it a value. Here is the math based on projected 1998 earnings of $1.96 x 27.7 = $54.29 on the high side and $1.96 x 25.8 (current P/E) = $50.57 on the low side. The RSI and Bollinger Bands indicators show the trading pattern for VVUS. The turnover in the number of shares shows the interest in VVUS. stocksmart.com "ROBERT M. COHEN & CO. REITERATES RATING ON VIVUS; Analyst Continues Speculative Buy and $50-1/2 Price Target GREAT NECK, N.Y., Oct. 24 /PRNewswire/ -- Robert M. Cohen & Company analyst Keith R. Bossey reiterated his speculative buy rating on Vivus, Inc. (Nasdaq: VVUS) and continued his 6-month price target of $50-1/2 following an announcement that Pfizer (NYSE: PFE) may introduce a competing impotence drug." Bossey noted, "While we admit that in most cases competition is unfavorable, Pfizer's entry into the impotence market may expand the market for all involved. Although Pfizer's Viagra may be deemed easier to use, we feel Vivus' on demand product will retain its current favorable market position."